Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors [Phase 2]

View source ↗

Summary

The document provides an update on a Phase 2 clinical trial sponsored by Hoffmann-La Roche evaluating biomarker-driven therapies for persistent or recurrent rar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING